Health
Dyadic C1 protein expression platform explored in fight against COVID-19 – Medical Plastics News
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced…
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced from Dyadics industrially proven proprietary and patented hyper-productive C1 gene expression platform.
The RBD was produced at three grams per liter (3 g/l) in only five days.
Dyadics C1 Rapid Recombinant Protein Manufacturing Platform can manufacture monoclonal antibodies (mAbs) more efficiently and faster than currently existing C…
-
General14 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General17 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News16 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business13 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher